Study immune changes after AML relapse after bone marrow transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how the immune system changes when acute myeloid leukemia (AML) comes back after a donor stem cell transplant. It may help researchers create more personalized treatment plans and future guidelines for how to care for people in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult with acute myeloid leukemia (AML) that has come back after an allogeneic stem cell transplant from a donor
- Your transplant came from a donor either related or unrelated, and it may have been bone marrow, peripheral blood stem cells, or cord blood
- You must be willing to sign the study consent form
- You must have stored blood/biologic samples available through a specific leukemia biobank (so researchers can study what’s happening in your body)
- You cannot join another clinical protocol if that protocol would block participation in other studies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at blood and bone marrow samples from people with acute leukemia to understand how the immune system reacts to the disease and treatment. The goal is to find better ways to treat leukemia.
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
This study tests an “immune cell therapy” made from a family donor to help children and young adults with AML stay in remission after chemotherapy. It may help reduce the chance that AML comes back, but eligibility depends on remission status, donor suitability, and avoiding certain infections or liver issues.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This study tests a new blood test to help predict whether acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will come back after a stem cell transplant. Early detection could help doctors treat relapse sooner.
This study is for adults with acute myeloid leukemia (AML) whose cancer has returned or is not responding to treatment. Researchers will analyze your leukemia cells to learn more about the disease and possibly find better treatments.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.